Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.61, read 2026-11-05
Ethical passes the values gate
Price31.84 USD
Fair value33.92
Ethical score80.5/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-27Read Accumulation32.89-3.2% to today Markdown gives way to Accumulation first Accumulation read since July
2026-10-02Read Markdown32.43-1.8% to today ✓Markup gives way to Markdown after an 8% slide in 5 weeks
2026-08-31Read Markup35.34-9.9% to today Distribution gives way to Markup after a 10% rise in 4 weeks
2026-08-01Read Distribution32.13-0.9% to today ✓Accumulation gives way to Distribution after an 18% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Halliburton holds its Markdown at $31.84. The statistical read favours the sellers, held for 187 days.
As held on the ledger · 2026-11-06
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 187 days
Price at the screen
$31.84
Valuation
15.20 trailing · 12.31 forward price to earnings
Values screen
PASS· score 80.5
Beta
0.84
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.52%
Below 33%
Interest-bearing debt is just 32.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
28.58%
Below 49%
Money owed to the company is 28.6% of assets, under the 49% limit.
Pass
Revenue purity
0.42%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Halliburton clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 33%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HAL's ethical verdict changes
Today HAL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic and this name passes it. Separately, community boycott lists cite this company: Cited by BDS movement for oilfield services and energy infrastructure support connected to Israeli energy operations in contested areas. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 6% discount to our $33.92 fair value, narrow competitive moat, 1.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 6.1% discount to the base estimate.
Where our models see it going: fair-value estimate $33.92, with a range of $26.10 to $39.00, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Oil services name flashes cheap but cycles bite
Picture a rig crew working flat out when crude prices spike. Halliburton rides those waves with a narrow moat, 15 percent return on equity and a forward multiple of just 12 times. Revenue sits flat and margins are only 7 percent, yet the shares trade right on our fair value line with an ethical screen cleared.
That low multiple draws attention in a sector where analysts see further upside. Still, a cyclical business showing zero top-line growth rarely offers a true bargain when earnings sit near their peak. The modest discount to our value does not change the pattern that has caught investors before.
Risk sits in the familiar energy trap where a low multiple signals fading demand rather than an overlooked gem. When the cycle turns, the narrow moat offers little protection and multiples can compress further.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HAL trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$34.61+5.2%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44.
2026-10-20Markdown$32.89+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$32.89+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$32.89+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$32.89+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$32.89+1.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$32.55+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$32.55+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Markdown$32.55+0.4%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 88%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (25 analysts) rates it buy, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
